Preparations to sue follow a two-year probe into whether the firms steer patients away from less-expensive medicines.
An interim report from the FTC claims PBMs profit at the expense of patients and independent stores by chasing higher-priced ...
Investing.com - The Federal Trade Commission (FTC) is gearing up to sue the top three pharmacy-benefit managers (PBMs) over their strategies for negotiating drug prices, including insulin.
WASHINGTON, DC: Federal Trade Commission Chair Lina Khan speaks during a discussion on antitrust ... [+] reforms at the Brookings Institution October 4, 2023. The FTC issued an interim report on ...
The Federal Trade Commission plans to sue the three largest pharmacy benefit managers in the country over practices that have kept drug prices artificially high, according to new reports from the ...
Improving the Patient Financial Experience Throughout the Patient Journey While many healthcare providers believe that improving the patient financial experience is a critical step for their ...
The Federal Trade Commission is planning to sue UnitedHealth, Cigna and CVS Health — the three largest pharmacy-benefit managers — over their tactics for negotiating prices for drugs including ...
The Inflation Reduction Act of 2022 was epochal in that--for the first time ever– it gave the federal government the power to ...
For more than two years, the Federal Trade Commission has been investigating whether pharmacy benefit managers steer patients ...
The Federal Trade Commission is preparing to sue the largest three pharmacy-benefit managers over their tactics for negotiating prices for drugs including insulin, after a two-year investigation ...